Since inception, Ensera’s ethos has been to solve complex challenges with bold, practical solutions, connecting design with delivery so clients can launch with confidence and patients get better products faster. Inflexion is supporting it to continue bringing reliable products to market.
Ensera is a leading global contract manufacturer serving the medical device and diagnostic sectors. A right-size global partner for clients who need pace, precision and assured quality, its name reflects the enhanced service it provides. Its integrated proposition connects award-winning healthcare product design and development with cleanroom end-to-end manufacturing capabilities, and pairs device expertise with final assembly and secondary packing for combination products. Its recent rebrand from SteriPack captures that breadth as well as its step-change in capacity and capability across Europe, North America and Asia.
Ensera specialises in complexity at pace – high-mix, low-to-medium volumes where agility, engineering depth and schedule assurance matter most. Operations are geared to flex quickly, with labour, equipment and validation strategies set up to cope with peaks. “We try to do everything we can to make sure that that drug, that therapy or that medical device is there when the patient and the physician need it,” notes CEO Jason Anderson. Its reputation means it works with a variety of clients including some of the world’s largest pharma and medtech companies, scale challengers, and mid-sized innovators across drug delivery, diagnostics, surgical and orthopaedics.
Its integrated offering is a differentiator for Ensera as it brings two complementary platforms together. On the medtech side, its design consultancies work together with manufacturing teams to take products from first principles through to commercial production. “We always try to find ways to get manufacturing involved earlier in design,” Jason says, adding that this cross-functional involvement leads to faster, safer industrialisation. “If you do integration well, you can bring a medical device to market faster.”
This also allows Ensera to compress timelines and reduce risk. Device programmes are set up as a single continuum, with manufacturing input from the outset so products are specified for stability, yield and repeatability long before tooling is cut. It is similar for pharma services. By uniting drug-delivery device know-how with final assembly and pack, Ensera’s clients avoid unnecessary hand-offs, shorten supply chains, and bring therapies to market with fewer variables – and thus fewer surprises. The result is an integrated path from device concept to product readiness.
Crucially, Ensera’s integrated approach is modular: clients can use a single service or the full offering. Even where Ensera provides just one stage, the proximity to adjacent steps – both culturally and operationally – tends to yield more better, more efficient outcomes.
Ensera’s footprint is local to end markets, offering clients the regulatory confidence of a global CDMO with the speed and service of a specialist. Its FDA-registered site in Florida has been expanded with three new pharma suites and significant cold-storage capacity – optimised to minimise time out of refrigeration – supporting final assembly, labelling, serialisation and aggregation for the US. In Europe, capacity for cleanroom manufacturing and final assembly supports customers via Poland and the UK. Malaysia extends reach for selected programmes where Asia proximity matters.
The company’s growth is a combination of organic and select strategic M&A. The acquisition of Kinneir Dufort shortly after Inflexion’s investment in 2022 strengthened Ensera’s design and development capabilities and established a European R&D centre of excellence. In summer 2025, the UK design and product development facility achieved EcoVadis Gold, placing it in the top 5% globally and highlighting the firm’s commitment to environmental and ethical performance as clients increasingly embed sustainability into product lifecycles.
Competition remains fragmented and continues to consolidate, often along specialist lines – by therapeutic area, process or device class. Ensera differentiates less by scale and more by service: pairing deep human-centred design with practical design-for-manufacture, then executing cleanly in highly regulated environments. That combination, and the ability to bridge device and pharma value chains, is still comparatively rare.
Demand remains resilient, particularly in pharma services, and Ensera is well placed to cater to it. Structural drivers include biosimilars as major biologics lose exclusivity and elevated activity around weight-management drugs, which are absorbing significant outsourced capacity. Additionally, customers are favouring shorter, local supply chains owing to uncertainty lengthening scenario planning cycles, with current challenges including the Inflation Reduction Act, tariffs, emerging biosecurity rules, etc. Ensera’s operating model, built around proximity and flexibility, is highly relevant for today’s demands.
Ensera is working with Inflexion to continue expanding capacity and capabilities across its network, deepening integration between design and manufacturing, and broadening component-manufacturing depth organically and through targeted M&A – to bring more of the value chain in-house where it helps clients. The pharma services platform will continue to grow in prominence as combination products become the norm and as customers increasingly seek out partners who can move at the speed modern markets demand.
Ambitious businesses can grow faster with the right capital and expertise, with Inflexion’s flexible funding offering minority or majority capital and access to a sizable team to accelerate growth. The Inflexion team has significant experience in supporting the growth of a number of healthcare companies of different sizes, including CNX Therapeutics, Rosemont Pharmaceuticals, Upperton, Pharmaspectra, Medivet, TPP and ELCG. All have access to Inflexion’s value acceleration strategies of M&A, digital enhancement, international expansion, commercial effectiveness, sustainability and talent management.
